352 related articles for article (PubMed ID: 31352979)
1. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
Loghavi S; Wang SA
Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
5. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
6. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Ragon BK; Savona MR
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S37-S42. PubMed ID: 28760301
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?
Sangiorgio VFI; Orazi A; Arber DA
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101139. PubMed ID: 32460987
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
Thota S; Gerds AT
Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
10. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
11. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
12. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
14. Advances in myelodysplastic/myeloproliferative neoplasms.
Prakash S; Arber DA; Bueso-Ramos C; Hasserjian RP; Orazi A
Virchows Arch; 2023 Jan; 482(1):69-83. PubMed ID: 36469102
[TBL] [Abstract][Full Text] [Related]
15. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
Fontana D; Elli EM; Pagni F; Piazza R
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
[TBL] [Abstract][Full Text] [Related]
17. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
[TBL] [Abstract][Full Text] [Related]
18. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.
Yin CC; Medeiros LJ; Bueso-Ramos CE
Int J Lab Hematol; 2010 Oct; 32(5):461-76. PubMed ID: 20626469
[TBL] [Abstract][Full Text] [Related]
20. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
